President Bush Names Niederhuber NCI Director

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

WASHINGTON—President Bush has appointed John E. Niederhuber, MD, as director of the National Cancer Institute (NCI). He is the Institute's 13th director, succeeding Andrew C. von Eschenbach, MD, who has been nominated as commissioner of the Food and Drug Administration (FDA).

Dr. Niederhuber brings a wealth of experience to NCI, as a former cancer center director, former chair of the National Cancer Advisory Board (NCAB), member of the Institute's senior management team for the last year, and acting NCI director since June 2006. In addition to his NCI administrative duties, Dr. Niederhuber holds a clinical appointment as a member of the medical staff at the NIH Clinical Centers.

Dr. Niederhuber joined NCI in September 2005 as deputy director for translational and clinical sciences and almost immediately became NCI's chief operating officer after Dr. von Eschenbach was named FDA acting director.

Dr. Niederhuber came to NCI from the University of Wisconsin School of Medicine, where he served as professor of surgery and oncology and as director of its Comprehensive Cancer Center from 1997 to 2002. Dr. Niederhuber earned his medical degree at Ohio State University School of Medicine, Columbus.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content